Ascletis Pharma Inc. has introduced optimistic topline outcomes from its part I a number of ascending dose (MAD) examine in wholesome topics for oral RNA-dependent RNA polymerase (RdRp) inhibitor ASC10 for COVID-19 remedy.
Ascletis’ ASC10 is an revolutionary orally obtainable double prodrug, which has a brand new and differentiated chemical construction from the one prodrug molnupiravir. After oral dosing, each ASC10 and molnupiravir are quickly and fully transformed in vivo into the identical energetic drug ASC10-A, also referred to as β-D-N4-hydroxycytidine (NHC). Double prodrug strategy considerably elevated oral bioavailability of energetic drug ASC10-A.
Ascletis part I information
The part I information demonstrated that each one doses of ASC10 together with 800 mg twice day by day had been protected and effectively tolerated in Chinese language topics. Security profiles between ASC10 and placebo remedies had been comparable. The publicity of energetic drug ASC10-A after twice day by day dosing 800 mg double prodrug ASC10 in Chinese language topics was 94% of that after twice day by day dosing 800 mg single prodrug molnupiravir in Japanese topics.
The plasma concentrations of the double prodrug ASC10 in Chinese language topics had been under detection restrict (0.2 ng/mL) after 800 mg dosing. Equally, the plasma concentrations of the one prodrug molnupiravir in American topics had been negligible after 800 mg dosing.
After physique weight normalization, the exposures of energetic drug ASC10-A are additionally equal between 800 mg double prodrug ASC10 in Chinese language topics and 800 mg single prodrug molnupiravir in American topics.
Meals had no impact on ASC10-A’s publicity, indicating that ASC10 will be taken with or with out meals.
Molnupiravir has been accredited or approved to be used in lots of international locations together with Japan and the U.S. Ascletis mentioned latest publications present molnupiravir demonstrated thrilling medical efficacy towards omicron infections in Chinese language sufferers.
Based mostly on the corporate’s part I outcomes of ASC10 and molnupiravir’s medical efficacy information in American, Japanese and Chinese language sufferers, 800 mg twice day by day has been chosen for the registrational trial.
The energetic drug ASC10-A has potent antiviral exercise towards varied Omicron variants equivalent to BA.5 and BA.2.75. Ascletis has filed a number of patent functions for ASC10 and its use globally.
“Based mostly on Part I outcomes, ASC10 could be very protected in Chinese language topics and its druggability is excessive. I imagine ASC10 has potential to play an necessary position in combating towards COVID-19 pandemic,” mentioned Yunqing Qiu, vp of the First Affiliated Hospital, College of Drugs, Zhejiang College and principal investigator of ASC10 part I examine.
“The part I medical information have confirmed the druggability of ASC10 for COVID-19. With the worldwide patent filings, we anticipate that ASC10 will make a contribution to combating towards COVID-19 pandemic inside and out of doors China,” mentioned Jinzi J. Wu, founder, chairman and CEO of Ascletis.